Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Jul 27

PMID 39065763

Authors

Jakub Michal Zimodro

Magda Mucha

Heiner K Berthold

Ioanna Gouni-Berthold

Affiliations

Soon will be listed here.

Abstract

Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease prevention. Although LLT might lead to different reductions in low-density lipoprotein cholesterol (LDL-C) levels in women and men, LLT diminishes cardiovascular risk equally effectively in both sexes. Despite similar LLT efficacy, the use of high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors is lower in women compared to men. Women achieve the guideline-recommended LDL-C levels less often than men. Greater cholesterol burden is particularly prominent in women with familial hypercholesterolemia. In clinical practice, women and men with dyslipidemia present with different cardiovascular risk profiles and disease manifestations. The concentrations of LDL-C, lipoprotein(a), and other blood lipids differ between women and men over a lifetime. Dissimilar levels of LLT target molecules partially result from sex-specific hormonal and genetic determinants of lipoprotein metabolism. Hence, to evaluate a potential need for sex-specific LLT, this comprehensive review (i) describes the impact of sex on lipoprotein metabolism and lipid profile, (ii) highlights sex differences in cardiovascular risk among patients with dyslipidemia, (iii) presents recent, up-to-date clinical trial and real-world data on LLT efficacy and safety in women, and (iv) discusses the diverse medical needs of women and men with dyslipidemia and increased cardiovascular risk.

References

Thierer J, Ekker S, Farber S . The LipoGlo reporter system for sensitive and specific monitoring of atherogenic lipoproteins. Nat Commun. 2019; 10(1):3426. PMC: 6668417. DOI: 10.1038/s41467-019-11259-w. View

Wadstrom B, Wulff A, Pedersen K, Jensen G, Nordestgaard B . Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2021; 43(34):3258-3269. DOI: 10.1093/eurheartj/ehab705. View

Belo L, Caslake M, Santos-Silva A, Castro E, Pereira-Leite L, Quintanilha A . LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis. 2004; 177(2):391-9. DOI: 10.1016/j.atherosclerosis.2004.07.023. View

Melo A, Rosa-E-Silva J, Rosa-E-Silva A, Poli-Neto O, Ferriani R, Vieira C . Unfavorable lipid profile in women with endometriosis. Fertil Steril. 2009; 93(7):2433-6. DOI: 10.1016/j.fertnstert.2009.08.043. View

Bartels A, ODonoghue K . Cholesterol in pregnancy: a review of knowns and unknowns. Obstet Med. 2016; 4(4):147-51. PMC: 4989641. DOI: 10.1258/om.2011.110003. View

Porkka K, Erkkola R, Taimela S, Raitakari O, Dahlen G, Viikari J . Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors. Ann Med. 1995; 27(2):193-8. DOI: 10.3109/07853899509031958. View

Liang J, Zhang B, Hu Y, Na Z, Li D . Effects of steroid hormones on lipid metabolism in sexual dimorphism: A Mendelian randomization study. Front Endocrinol (Lausanne). 2023; 13:1119154. PMC: 9886494. DOI: 10.3389/fendo.2022.1119154. View

Lakoski S, Lagace T, Cohen J, Horton J, Hobbs H . Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009; 94(7):2537-43. PMC: 2708952. DOI: 10.1210/jc.2009-0141. View

Ruiz-Sanz J, Navarro R, Martinez R, Hernandez M, Matorras R, Ruiz-Larrea M . No effect of menstrual cycle on LDL oxidizability and particle size. Maturitas. 2007; 57(3):253-60. DOI: 10.1016/j.maturitas.2007.01.008. View

10.

Agarwala A, Deych E, Jones L, Sturm A, Aspry K, Ahmad Z . Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2022; 17(1):150-156. DOI: 10.1016/j.jacl.2022.11.009. View

11.

Seidah N, Awan Z, Chretien M, Mbikay M . PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114(6):1022-36. DOI: 10.1161/CIRCRESAHA.114.301621. View

12.

Ndzie Noah M, Adzika G, Mprah R, Adekunle A, Adu-Amankwaah J, Sun H . Sex-Gender Disparities in Cardiovascular Diseases: The Effects of Estrogen on eNOS, Lipid Profile, and NFATs During Catecholamine Stress. Front Cardiovasc Med. 2021; 8:639946. PMC: 7907444. DOI: 10.3389/fcvm.2021.639946. View

13.

Smith G, Reeds D, Okunade A, Patterson B, Mittendorfer B . Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. J Clin Endocrinol Metab. 2014; 99(7):E1306-10. PMC: 4079308. DOI: 10.1210/jc.2013-4470. View

14.

Peters S, Colantonio L, Zhao H, Bittner V, Dai Y, Farkouh M . Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol. 2018; 71(16):1729-1737. DOI: 10.1016/j.jacc.2018.02.032. View

15.

Maas A, Appelman Y . Gender differences in coronary heart disease. Neth Heart J. 2011; 18(12):598-602. PMC: 3018605. DOI: 10.1007/s12471-010-0841-y. View

16.

Myasoedova V, Rimbert A, Camera M, Le May C, Capoulade R, Cariou B . LDL lowering effect of PCSK9 inhibition is reduced in women. Eur Heart J Cardiovasc Pharmacother. 2023; 9(4):337-342. PMC: 10236513. DOI: 10.1093/ehjcvp/pvad009. View

17.

El Khoudary S, Hutchins P, Matthews K, Brooks M, Orchard T, Ronsein G . Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause. J Clin Endocrinol Metab. 2016; 101(9):3419-28. PMC: 5010578. DOI: 10.1210/jc.2016-2144. View

18.

Ray K, Raal F, Kallend D, Jaros M, Koenig W, Leiter L . Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2022; 44(2):129-138. PMC: 9825807. DOI: 10.1093/eurheartj/ehac594. View

19.

Fulcher J, OConnell R, Voysey M, Emberson J, Blackwell L, Mihaylova B . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976):1397-405. DOI: 10.1016/S0140-6736(14)61368-4. View

20.

El Khoudary S . HDL and the menopause. Curr Opin Lipidol. 2017; 28(4):328-336. DOI: 10.1097/MOL.0000000000000432. View